Mikael leads the Worldwide Research, Development and Medical (WRDM) organization at Pfizer, which is responsible for the development of all compounds through proof of concept, and provides pharmaceutical sciences, safety and medical support to the entire R&D pipeline and all marketed products. The WRDM group contains all Pfizer research units, including Oncology, Internal Medicine, Inflammation & Immunology, Vaccines and Rare Disease, as well as the Centers for Therapeutic Innovation (CTI). Mikael has worldwide responsibility for Pfizer’s groups in medical, safety and external R&D innovation, in addition to science-based teams in pharmaceutical sciences, drug safety R&D, and large and small molecule discovery and development. Mikael is a member of the Executive Leadership Team and Pfizer’s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities.
Mikael earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden and was appointed Adjunct Professor in Tumor Immunology. He is a governor of the New York Academy of Sciences and serves on the PhRMA Research & Development Leadership Forum, the PhRMA Foundation Board of Directors, and the Board of Karyopharm Therapeutics. Mikael is a member of the Board of Overseers – Scripps Research Institute as well as a Foreign Member of The Royal Swedish Academy of Engineering Sciences. Since 2014, Mikael has co-chaired the Accelerating Medicine Partnership (AMP) with National Institutes of Health (NIH) Director Francis S. Collins. Mikael advised the Obama Administration on R&D as well as Vice President Biden’s Cancer Moonshot Initiative to accelerate cancer research.
Mikael is a named inventor on several patents and has published approximately 150 articles in international journals.